Clinical Cancer Drugs
Volume 6, 2 Issues, 2019
ISSN: 2212-6988 (Online)
ISSN: 2212-697X (Print)
This journal supports open access
ISSN: 2212-6988 (Online)
ISSN: 2212-697X (Print)
This journal supports open access
Contents
Clinical Cancer Drugs, Volume 2 - Number 1
Preface
Editorial
Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
, 2(1): 4 - 15Mizue Terai and Takami Sato
DOI: 10.2174/2212697X02666150203212041
Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
Recent Clinical Advances in the Treatment of Cutaneous Melanoma
, 2(1): 16 - 28Martin Greco, Maximiliano Mestroni, Maximo de la Vega, Gonzalo Recondo, Matias E. Valsecchi, Gonzalo Recondo and Enrique Diaz Canton
DOI: 10.2174/2212697X02666150203212708
Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
, 2(1): 29 - 37Marlana Orloff, Shingo Sato, Matias E. Valsecchi and Takami Sato
DOI: 10.2174/2212697X02666150203213809
Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
, 2(1): 38 - 43Maximo de la Vega, Matias E. Valsecchi, Martin Greco, Gonzalo Recondo, Gonzalo Recondo and Enrique Diaz Canton
DOI: 10.2174/2212697X02666150203212942
Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma
, 2(1): 44 - 53Karen E. Thudium, Lance Wollenberg, Cory Mavis, Jenny Gu, Gerald J. Fetterly, Myron S. Czuczman and Francisco J. Hernandez-Ilizaliturri
DOI: 10.2174/2212697X02666150128003659
Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma
Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
, 2(1): 54 - 60Koichi Momiyama, Hidenari Nagai, Yu Ogino, Takanori Mukozu, Daigo Matsui, Teppei Matsui, Noritaka Wakui, Mie Shinohara, Yoshinori Igarashi and Yasukiyo Sumino
DOI: 10.2174/2212697X02666150313003755
Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
, 2(1): 61 - 70Kelly Lien, Michelle Rocha, Elisa Tran, Van C. Hoang, Annabelle Chow and Urban Emmenegger
DOI: 10.2174/2212697X02666150331202809
Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
  |
Editor-in-Chief
Giulio Francia
The University of Texas
El Paso, TX
USA
Biography
View Full Editorial Board
The University of Texas
El Paso, TX
USA
Biography
Biography of Giulio Francia
Dr. Francia began his career by undertaking a PhD with Dr. Ian Hart at the Imperial Cancer Research Fund in London, UK, which has since evolved into Cancer UK. After his PhD, he trained with Dr. Robert Kerbel in Toronto, Canada, on aspects of metastasis, therapies for metastatic disease, and tumor resistance to therapy. He is now Assistant Professor at The University of Texas at El Paso, where he is attempting to set up a research program that is internationally recognized for pioneering new cancer therapeutic ideas, and for generating in vivo models to help translate laboratory findings into the clinic - by developing new metastatic tumor models, and by refining those he has already established.
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Clinical Cancer Drugs was introduced in 2014 with the assistance of Dr. Giulio Francia, who is the current Editor-in-Chief serving since 2014.
Webmaster Contact: info@benthamscience.net